The complaint says Mr. Richards received more than 500 kilograms of hydroxychloroquine and 50 kilograms of chloroquine from a Chinese vendor. It also says the drugs were misbranded and presented as “Boswellia serrata extract.”
Mr. Richards faces one misdemeanor count of receipt of misbranded drugs in interstate commerce.
In March, Utah bought 20,000 units of hydroxychloroquine from Meds in Motion for $800,000, planning to use the drug as a COVID-19 treatment. However, the state dropped the deal and was refunded in April after the FDA issued a warning discouraging the malaria drug’s use as a COVID-19 treatment, according to The Salt Lake Tribune. There is currently no confirmation as to whether Mr. Richards’ charge is connected to Utah’s canceled deal.
More articles on pharmacy:
Fresenius Kabi recalls NSAID due to presence of particulate matter
CVS Health names new chief people officer
Ohio Medicaid names a single, state-controlled PBM
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
